CoChat

The use of metformin in women with polycystic ovary syndrome: an updated review

Open access
Notaro, Adriana Leal Griz, Neto, Filipe Tenorio Lira · 2022 · Journal of Assisted Reproduction and Genetics

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Purposes Polycystic ovary syndrome (PCOS) is a major cause of female infertility, being present in up to 20% of women of childbearing age. Insulin resistance (IR) plays an important role in the pathophysiology of PCOS; therefore, its treatment may benefit women with the syndrome. The main drug used for IR management is metformin (MT). We aim to review the literature on the use of metformin in women with PCOS.Methods Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases. The research was restricted to articles published in English. Initially, only published meta-analyses were included, in the absence of meta-analyzes, RCT and well-designed prospective studies were used.Results Metformin increases success rates and decreases complication rates when used as an adjunctive medication for ovulation induction during low complexity assisted reproduction treatments and during ovarian stimulation for in vitro fertilization in women with PCOS. Evidence about the effect of metformin on fetal and obstetric complication rates is conflicting. Metformin is associated with high incidence of gastrointestinal symptoms; however, serious adverse effects are rare and there is no evidence of teratogenicity.Conclusion For women with PCOS, metformin is a good adjunctive medication for ovulation induction/stimulation for high and low complexity assisted reproduction therapies. The adverse effects are mostly mild, and there is no risk of teratogenicity, but the risk of long-term complications for the offspring is not yet defined. High heterogeneity of the studies limits extrapolation of findings, and further research is needed to determine which women will benefit most from the medication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10815-022-02429-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 100

Metadata

Authors
Notaro, A. L. G., & Neto, F. T. L.
Venue
Journal of Assisted Reproduction and Genetics
Published
2022-02-14
Volume
39
Issue
3
Pages
573-579
ISSN
  • 0740-7769 (ISSN-L)
  • 1058-0468
  • 1573-7330
OpenAlex
W4212921576
Cited by
83
References
48
Citations by year
2026: 19 · 2025: 18 · 2024: 26 · 2023: 16 · 2022: 4
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Assisted Reproduction and Genetics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
Keywords
metformin, polycystic ovary syndrome, insulin resistance, ovulation induction, in vitro fertilization, assisted reproduction, female infertility, teratogenicity, gastrointestinal adverse effects
MeSH terms
Clomiphene, Female, Fertility Agents, Female, Humans, Hypoglycemic Agents, Infertility, Female, Insulin Resistance, Metformin, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy, Prospective Studies, Pregnancy Rate, Live Birth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of metformin in women with polycystic ovary syndrome: an updated review. https://app.cochat.ai/papers/10.1007/s10815-022-02429-9
The paper
Notaro, A. L. G., & Neto, F. T. L. (2022). The use of metformin in women with polycystic ovary syndrome: an updated review. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-022-02429-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.